Results 1 to 10 of about 35,072 (188)
Frontiers in Pharmacology, 2021 Background: From October 2018, adalimumab biosimilars could enter the European market. However, in some countries, such as Netherlands, high discounts reported for the originator product may have influenced biosimilar entry.Objectives: The aim of this ...
Evelien Moorkens +2 more
exaly +3 more sources
Drugs, 2006 Adalimumab, a fully human monoclonal antibody, is a tumour necrosis factor antagonist that has been investigated for efficacy in psoriatic arthritis, based on well-established use of the drug in rheumatoid arthritis. In well-controlled Phase III trials, adalimumab (40 mg administered subcutaneously every other week) has shown efficacy in adult patients
Dene, Simpson, Lesley J, Scott
europepmc +5 more sources
Frontiers in Pharmacology, 2019 Background: Few studies have evaluated the effectiveness of adalimumab in the real-life setting in psoriatic arthritis (PsA).Objective: To evaluate the 2-year retention rate of adalimumab in PsA patients.
Salvatore D`Angelo +2 more
exaly +3 more sources
Dermatology and Therapy, 2023 This Summary of Research overviews the results of the VOLTAIRE-X study (NCT03210259), which looked at what happened when people with plaque psoriasis continually took the adalimumab reference product (adalimumab RP; known by the brand name Humira®) or ...
Alan Menter
doaj +1 more source
Effect of adalimumab on quality of life in patients with active ankylosing spondylitis [PDF]
Xin yixue, 2023 Objective To evaluate the efficacy of adalimumab in improving the quality of life of adult patients with active ankylosing spondylitis （AS）. Methods This was a post-hoc study of the randomized，double-blind controlled clinical trial of adalimumab and ...
Cao Shuangyan, Shao Zhanqin, Gu Jieruo
doaj +1 more source
Drugs in R&D, 2023 Background Adalimumab-aqvh/CHS-1420 (YUSIMRYTM) (hereafter referred to as adalimumab-aqvh) was recently approved by the US Food and Drug Administration as a biosimilar for adalimumab.
Yijia Jiang +8 more
doaj +1 more source
Frontiers in Pediatrics, 2021 Introduction: Adalimumab is effective in inducing and maintaining remission in children with inflammatory bowel diseases (IBD). Therapeutic drug monitoring is an important strategy to maximize the response rates, but data on the association of serum ...
Marianna Lucafò +10 more
doaj +1 more source
Adalimumab in dermatology [PDF]
British Journal of Clinical Pharmacology, 2008 Adalimumab is a biological agent, one of the tumour necrosis factor‐alpha inhibitors. Pivotal studies evaluating its efficacy in plaque psoriasis (CHAMPION, REVEAL) and psoriatic arthritis (PsA) (ADEPT) were carried out in recent years. Adalimumab proved highly effective in psoriasis patients and in PsA patients previously unresponsive to nonsteroidal ...
Traczewski, Paweł, Lidia Rudnicka
openaire +2 more sources
Clinical and Translational Science, 2021 This study aimed to demonstrate pharmacokinetic (PK) equivalence of a single dose of the proposed adalimumab biosimilar CT‐P17 to United States‐licensed adalimumab (US‐adalimumab) and European Union‐approved adalimumab (EU‐adalimumab). This double‐blind,
Kyung‐Sang Yu +19 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Delanzomib is a novel proteasome inhibitor initially developed for treating multiple myeloma. It was found to inhibit the expression of tumor necrosis factor alpha (TNF-α). This study aimed to investigate the ameliorating effect of delanzomib on collagen-
Lei Wang +5 more
doaj +1 more source